Collaborative Research and Development Agreement, Optional Extension Period

No definition available.

Name:	cdxs_CollaborativeResearchandDevelopmentAgreementOptionalExtensionPeriod
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Revenue, Contingent Receivables

+ References

No definition available.

+ Details

Name:	cdxs_LicenseRevenueContingentReceivables
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue Recognition, Duration to Pay After License Effective Date

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionDurationtoPayAfterLicenseEffectiveDate
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Event of Counterparty Exercising Alternative Option

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionEventofCounterpartyExercisingAlternativeOption
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Additional Milestones, Maximum Milestone Receivable

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionMilestoneMethodAdditionalMilestonesMaximumMilestoneReceivable
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue Recognition, Milestone Revenue

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionMilestoneRevenue
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Progress Payment, Amount

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionProgressPaymentAmount
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Target Sales for Sales Milestone

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionTargetSalesforSalesMilestone
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Term of collaborative research and development agreement.

+ References

No definition available.

+ Details

Name:	cdxs_TermOfCollaborativeResearchAndDevelopmentAgreement
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=cdxs_MerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cdxs_NestecLtd.NestleHealthSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cdxs_GlobalDevelopmentOptionandLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cdxs_PortonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cdxs_PortonAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cdxs_AgreementTypeAxis=cdxs_TechnologyTransferCollaborationandLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cdxs_AgreementTypeAxis=cdxs_SupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cdxs_CustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cdxs_AgreementTypeAxis=cdxs_ResearchandDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cdxs_FineChemicalCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cdxs_AgreementTypeAxis=cdxs_SalesBasedMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - Textual (Details) - USD ($)	1 Months Ended						3 Months Ended		6 Months Ended
	Apr. 30, 2018	Oct. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Aug. 31, 2015	Feb. 29, 2012	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue							$ 18,966,000		$ 18,966,000		$ 13,793,000
Research and development revenue							9,815,000	$ 3,747,000	17,694,000	$ 6,131,000
Deferred revenue							4,460,000		4,460,000		12,292,000
Merck [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales revenue							2,700,000	3,200,000	7,200,000	5,000,000
Merck [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from license fees received					$ 5,000,000
License and services revenue							1,000,000	900,000	1,900,000	1,800,000
Nestec Ltd. (Nestle Health Sciences) [Member] \| Global Development, Option and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue							2,300,000		2,300,000		6,800,000
Milestone revenue		$ 14,000,000
Revenue recognized							1,800,000	0	4,500,000	0
Progress payment amount									4,000,000
Event of counterparty exercising alternative option		$ 3,000,000
Duration to pay after license effective date		60 days
Nestec Ltd. (Nestle Health Sciences) [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development revenue							600,000	0	1,200,000	0
Deferred revenue							800,000		800,000		1,100,000
Porton [Member] \| Porton Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue							500,000		500,000		0
Milestone revenue	$ 500,000
Research and development revenue							0	0	0	0
Technology Transfer, Collaboration and License Agreement [Member] \| Merck [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone receivable					$ 15,000,000
Technology Transfer, Collaboration and License Agreement [Member] \| Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License revenue, contingent receivables							5,750,000		5,750,000
Technology Transfer, Collaboration and License Agreement [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License revenue, contingent receivables							38,500,000		38,500,000
Supply Agreement [Member] \| Merck [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License and services revenue							0	300,000	1,300,000	700,000
Term of collaborative research and development agreement						5 years
Optional extension period						5 years
Deferred revenue							5,200,000		5,200,000		1,500,000
Supply Agreement [Member] \| Customer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue							2,000,000		2,000,000		700,000
Milestone revenue				$ 800,000
Research and Development Agreement [Member] \| Fine chemical customer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Term of collaborative research and development agreement			21 months
Deferred revenue							1,100,000		1,100,000		$ 3,100,000
Milestone revenue			$ 3,000,000
Research and development revenue							$ 4,500,000	$ 900,000	$ 5,900,000	$ 900,000
Research and Development Agreement [Member] \| Maximum [Member] \| Nestec Ltd. (Nestle Health Sciences) [Member] \| Global Development, Option and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue		$ 86,000,000
Sales-Based Milestone [Member] \| Nestec Ltd. (Nestle Health Sciences) [Member] \| Global Development, Option and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Target sales for sales milestone		1,000,000,000
Sales-Based Milestone [Member] \| Maximum [Member] \| Nestec Ltd. (Nestle Health Sciences) [Member] \| Global Development, Option and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue		$ 250,000,000